Marina Chiara Garassino

About

Marina Chiara Garassino, MD, is a Professor of Medicine and Director of Thoracic Programs in the Section of Hematology/Oncology at the University of Chicago. She is an internationally recognized thoracic medical oncologist specializing in the care of patients with non–small cell lung cancer (NSCLC), small cell lung cancer (SCLC), mesothelioma, and thymic malignancies. Dr. Garassino received her medical degree and completed her oncology training at the Università degli Studi di Milano, followed by clinical fellowships at San Raffaele Scientific Institute, the Istituto Nazionale dei Tumori (INT) in Milan, and Christie’s Hospital in Manchester (UK). Before joining UChicago in 2021, she served as Chief of the Medical Thoracic Oncology Unit at INT Milan, one of Europe’s leading comprehensive cancer centers. She also holds a Master’s in Oncology Management from Bocconi University, reflecting her longstanding interest in redesigning cancer care pathways. Her research has helped reshape global standards of care in lung cancer, including leading pivotal clinical trials such as KEYNOTE-189, PACIFIC, and KEYNOTE-671, which have established chemo-immunotherapy as a standard treatment for metastatic NSCLC and integrated immunotherapy into earlier disease stages. Dr. Garassino has contributed to the development of targeted therapies, authored over 350 peer-reviewed publications, and is at the forefront of AI-driven and multimodal research in thoracic oncology. She co-leads international…

Research topics

• Medicine
• Internal medicine
• Oncology
• Biology
• Pathology
• Surgery
• Environmental health
• Intensive care medicine
• Chemistry
• Family medicine

Selected publications

• Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

  Cancer Discovery · 2023 · 178 citations

  Molecular modifiers of KRASG12C inhibitor (KRASG12Ci) efficacy in advanced KRASG12C-mutant NSCLC are poorly defined. In a large unbiased clinicogenomic analysis of 424 patients with non-small cell lung cancer (NSCLC), we identified and validated coalterations in KEAP1, SMARCA4, and CDKN2A as major independent determinants of inferior clinical outcomes with KRASG12Ci monotherapy. Collectively, comutations in these three tumor suppressor genes segregated patients into distinct prognostic subgroups…

  DOI

• Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

  Journal of Clinical Oncology · 2024 · 103 citations

  PURPOSE: The open-label, phase III EVOKE-01 study evaluated sacituzumab govitecan (SG) versus standard-of-care docetaxel in metastatic non-small cell lung cancer (mNSCLC) with progression on/after platinum-based chemotherapy, anti-PD-(L)1, and targeted treatment for actionable genomic alterations (AGAs). Primary analysis is reported. METHODS: intravenous infusion on day 1) in 21-day cycles. Primary end point was overall survival (OS). Key secondary end points were investigator-assessed progressi…

  DOI

• APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer

  npj Precision Oncology · 2026-01-29 · 1 citations

  articleOpen access

  Identifying predictive and resistance biomarkers remains one of the most relevant unmet needs in clinical cancer research. Artificial Intelligence (AI) represents a powerful tool to develop predictive algorithms tailored to individual patients. Thanks to its ability to process large quantities of heterogeneous, patient-level information, the AI-based approach is progressively fostering the growth of a data-driven paradigm to complement traditional, hypothesis-driven clinical research. However, t…

  PublisherDOI

• Probing Cellular Activity Via Charge‐Sensitive Quantum Nanoprobes

  Advanced Materials · 2026-02-04 · 1 citations

  articleOpen access

  Nitrogen-vacancy (NV) based quantum sensors hold great potential for real-time single-cell sensing with far-reaching applications in fundamental biology and medical diagnostics. Although highly sensitive, the mapping of quantum measurements onto cellular physiological states has remained an exceptional challenge. Here, we introduce a novel quantum sensing modality capable of detecting changes in cellular activity. Our approach is based on the detection of environment-induced charge depletion wit…

  PublisherOA PDFDOI

• Deep learning discriminates thymic epithelial tumors’ histological subtypes using digital pathology

  Annals of Oncology · 2025-12-11 · 1 citations

  articleSenior author
  PublisherDOI

Frequent coauthors

• Claudia Proto

  Fondazione IRCCS Istituto Nazionale dei Tumori

  232 shared

• Filippo de Braud

  University of Milan

  214 shared

• Giuseppe Lo Russo

  Fondazione IRCCS Istituto Nazionale dei Tumori

  210 shared

• Diego Signorelli

  Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

  204 shared

• Monica Ganzinelli

  Fondazione IRCCS Istituto Nazionale dei Tumori

  187 shared

• Roberto Ferrara

  Vita-Salute San Raffaele University

  184 shared

• Luis Paz‐Ares

  157 shared

• Valter Torri

  Mario Negri Institute for Pharmacological Research

  156 shared

Education

• M.D.

  Università degli Studi di Milano

• Other, Oncology Management

  Bocconi University

Awards & honors

• Fellow of ESMO
• The Lancet Commissioner
• Founder and honorary president of Women for Oncology Italy
• Co-Chair for Women in Thoracic Oncology

Similar researchers at University of Chicago

• Gini Flemingh-133
• Hedy Kindlerh-109
• Rita Nandah-65